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EFFECT OF COMBINED THERAPY IN PATIENTS 
WITH UROLITHIASIS OF LOWER URINARY PH 
Wei Xi-YUAN 
Chienese research fellow of Department of Urology, Hyogo College of Medicine 
(Director: Prof. F. !koma) 
The effect of combining therapy with hydrochlorothiazide, allopurinol and systemic 
alkalization for urolithiasis with lower urinary pH was examined. A total of 90 patients were 
followed up for I to 3 years, the average follow up period being 18 months. The total stone 
disappearance rate was 60% (kidney stone), 74% (ureter stone) and 20% (bladder stone). 
Large amounts of thiazide diuretics, potassium and magnesium were intravenously administered 
to a patient with systemic alkalization at slow infusion speed, neither serious side effects nor 
complication occurred. This method is simple and an effective remedy. It is also very practical 
in the developing countries of the third world. 
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INTRODUCTION 
The morbidity of urolithiasis is con-
tinuously increasing in China. The most 
common type of caculi are uric acid stones, 
urate stones, calcium oxalate stones and 
mixed calculi. In some sea-side areas 
the proportion is as high as to 40% or 
more7 ,16). Many patients with calcium 
oxalate stone have been associated with 
hyperuricaciduria. The urinary pH of 
patients with hyperuric-aciduria were 
acidic. Low pH urine promotes formation 
of urinary calculi. Ninety patients with 
urolithiasis whose urine specimens showe 
a pH lower than 5.5 were treated with 
administraton of large amounts of hydro-
chlorothiazid allopurinol and systemic 
alkalization between January, 1983 and 
December, 1985. The results obtained sug-
gest that this complex treatment could not 
only prevent stone formation but also 
dissolve and discharge urinary calculi. 
MATERIALS AND METHODS 
The patients (male 82, female 8) were 
between 22 and 79 years old. Their chief 
complaints were typical renal colic. Uri-
nalysis showed a pH lower pH than 5.5 
and either macro-or microscopic hematuria 
was observed on their first visit. Blood 
chemistory revealed a normal range of 
serum calcium and phosphorus but serum 
level of uric acid elevated in 63 cases (70 
%) ranging from 7.5 to 14.5 mgJdl. 
The diagnosi of urolithiasis was estab-
lished by the detection of a positive or 
negative filling defect on radiograph, in-
cluding plain film, excretery urography 
(IVP) or retrograde pyelography. Also 
computerized tomography (CT scans) and 
ultrasonography often were used to confirm 
the presence of the calculi. With the latter 
techniques urinary calculi and or hydro-
nephrosis (due to ureteric obstruction) 













3 to 12 months 
2. Inj. Sodium lactate M/6-500 ml 
Inj. Magnesium sulfate 10%-10 ml 
aa mixt i.v.gtt. q.d. continued 7 to 10 
days, rest 3 days re-injection 
3. At the same time encourage patients 
a large fluid intake2,lD to increase 
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Position of stones 
Kidney Ureter Bladder 










Fig. 1. Diagonosis of urinary calculi 
Position of stones 
Response of treatment 
Kidney Ureter Bladder 
Radiograph 
Plain film stone shadow 
Dissolution 2/10 28/38 0 
Decrease 4/10 8/38 1/4 
No response 4/10 2/38 0 
Increase 0 0 0 
LV.P. 
Hydronephrosis 
Disappearance 1/1 33/35 
Aggravation 0 0 
C.T. Scans 
Decrease 6/10 1/8 
No response 4/10 1/8 
Increase 0 0 
Ultrasonography 
Hydronephrosis 
Disappearance 1/1 45/50 
Aggravation 0 0 
Stone shadow 
Dissolution 10/18 40/45 1/5 
Decrease 4/18 1/5 
No response 4/18 5/45 3/5 
Increase 0 0 
Stone discharge 8/20(40%) 35/65 (54%) 1/5 (20%) 
Total stone disappearance 12/20(60%) 48/65(74%) 1/5 (20%) 
Fig. 2. Result of treatment 
urinary volume to at least 2,000 ml 
every day. 
RESULTS: 
The patients have been followed for 12 
to 36 months (mean 18 months) (Fig. 2). 
DISCUSSION 
Thiazide diuretics could lower urinary 
calcium excretion. During the last decade 
thiazides have been extensively used in the 
prevention of recurrent urolithiasis forma-
tion1,3). Thiazides are particularly indica-
ted in the presence of all types of 
hypercalciurias,IS,18). Thiazide therapy has 
also been claimed to be equally effective 
in patients with normocalciuriam . Long-
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term thiazide treatment might result in 
potassium and magnesium deficiency. Com-
bined treatment with thiazide and magne-
sium appears to decrease urinary calcium 
and increase urinary magnesium resulting 
in a reduced Ca/Mg quotient and appa-
rently a lower risk of forming urine super-
saturated with calcium\), Both potassium 
and magnesium were, therefore, admini-
stered at the same time in our routine 
therapeutic regimens. 
Three different processes: nucleation, 
crystal growth and aggregation are consi-
dered to be important in the formation 
of urinary stone. The nucleus of mixed 
urinary stones containing calcium fre-
quently was urate and or uric acid or 
bothJ3). Allopurinol, a xanthine oxidase 
inhibitor, reduces the serum uric acid 
level and reduces the urinary excretion of 
uric acid and urate, which decrease nu-
clea tion of urinary stones6 ,9). 
The administration of allopurinol has 
also been shown to inhibit the growth and 
aggregation of crystals of calcium oxalate 
and calcium phosphates in urine14 ,15,l7). 
This may be accomplished by a reduced 
excretion of urate secondarily followed by 
increased concentrations of inhibitors of 
growth and aggregation. The increased 
crystal growth inhibition during administ-
ration of allopurinol might be of founda-
mental importance since it suggest that 
allopurinol might is of value as a prophy-
latic method in patient with different 
types of abnormalities in their urine 
composition9,12,14) • 
Since the type of uric acid stone forma-
tion is often associated with a persistently 
acidic urine4), the use of alkalizing agents 
is an important aspect of therapy. Stone 
formation occurs because uric acid is in 
associated form in the presence of acidic 
urine and supersaturation and subsequent 
crystallization are likely. When urinary 
pH approaches 7.0 or more then half of 
the uric acd is in the dissociated form 
and not only is crystallization unlikely 
but dissolution often occurs2 ,lO). When a 
patient is administered oral sodium bicar-
bonate or sodium potassium citrate, uri-
nary alkalization with this agent is inter-
mittentS). On the other hand, intravenous 
infusion with one-sixth molar sodium la-
ctate resulted in sustained urinary alkali-
zation, which may be effective in stone 
dissolution. 
An infusion rate of 40~sO ml per hour 
seemed to be safe and often was sufficient 
to maintain adequate urinary alkalization. 
Urinary pH and monitored and usually 
was maintained at 7.0 to 7.5 within 4~6 
hours. This could alkalify the urine 
rapidly to effect dissolution of obstructing 
ureteral stones and uric acid stones within 
renal pelvisS,lO). Sodium lactate is a 
racemic salt in which the levo form is 
oxidized to bicarbonate and the dextre 
form is converted to glycogen. One-sixth 
molar sodium lactate solution is isotonic 
and when metabolized in the normal man-
ner it has the potential for acid neutrali-
zation equivalent to 340 ml of a 5% 
sodium bicarbonate solution and an anti-
ketogenic effect equivalent to 500 ml of a 
6% dextrose solution. Sodium lactate is 
completely converted to bicarbonate in 
only 1 to 2 hoursS). As with other alkali-
zation regimens excess sodium loading is 
possible with this combined therapy. Serum 
electrolytes, blood pressure and cardiac 
status must be monitored carefully. Al-
though our method is somewhat complex, 
neither serious side effects nor compli-
cations occurred in our series because the 
infusion speed was kept low. 
The auther thank Dr. Hiroki Shima for editorial 
assistance in preparing this manuscript. 
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による大量のサイアザイ ド利尿剤,カ リウム,マ グネ
シウム投与による重篤な副作用や合併症は認められな
かった.こ の方法は簡単でかつ効果的であり,発 展途
上国においても施行可能な治療であると思われる.
